Rev-56 targets a key driver of increased exacerbations, hospitalizations, disease progression and mortality in NCFB — chronic Pseudomonas, an underlying cause with no indicated therapies — which results in a steady decline in lung function and quality of life. Designed for inhaled delivery and with a novel mechanism of action, Rev-56 has the potential for once-daily dosing and is entering Phase 1 clinical development in 2026.¹

A dry-powder formulation of Rev-56, intended to enhance patient convenience and expand the program’s reach, is approaching candidate selection and poised to begin IND-enabling studies.

We are also positioned to strategically extend our targeted, purpose-built medicines into other chronic and recurrent conditions.

1. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93022C00061